Fairbanks R&D Tax Credit and Economic Development

R&D Tax Credits for Fairbanks, Alaska Businesses

The top five R&D companies in Fairbanks, Alaska, include the University of Alaska Fairbanks Research Institute, Fort Knox Gold Mine, Fairbanks Memorial Hospital, Alaska Railroad Corporation, and Cold Climate Housing Research Center. The R&D tax credit can help these companies reduce their tax burdens, allowing them to reinvest savings into research, development, and operational efficiency. By leveraging the R&D tax credit, these companies can foster innovation, improve business performance, and contribute to the economic development of Fairbanks.

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 3000 C St, Anchorage, Alaska is less than 360 miles away from Fairbanks and provides R&D tax credit consulting and advisory services to Fairbanks and the surrounding areas such as: North Pole, Ester, Salcha, Fox
and Nenana.

If you have any questions or need further assistance, please call or email our local Alaska Partner on (907) 313-3350.
Feel free to book a quick teleconference with one of our Alaska R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Fairbanks, Alaska Patent of the Year – 2024/2025

University Of Alaska Fairbanks has been awarded the 2024/2025 Patent of the Year for their innovative approach to metabolic modulation. Their invention, detailed in U.S. Patent No. 11911408, titled ‘Synergistic formulations of adenosine receptor modulating agents and anticholinergics’, introduces a novel pharmaceutical composition designed to suppress metabolism without causing hypotension or bradycardia.

This formulation combines an A1 adenosine receptor (A1AR) agonist, such as 6-N-cyclohexyladenosine (CHA), with an A1AR antagonist like 8-(p-sulfophenyl)theophylline (8-SPT), and an anticholinergic agent, typically atropine. The unique combination allows for controlled metabolic suppression, which is particularly beneficial in clinical settings requiring induced hypothermia or metabolic depression without the adverse cardiovascular effects commonly associated with such treatments.

Preclinical studies have demonstrated that this synergistic approach effectively reduces metabolic rate and body temperature while maintaining stable blood pressure and heart rate. The composition’s ability to mitigate CHA-induced hypotension and bradycardia makes it a promising candidate for applications in trauma care, surgery, and other medical procedures where controlled metabolic suppression is necessary.

With this patent, the University of Alaska Fairbanks continues to contribute to advancements in medical science, offering a safer and more effective method for managing metabolic processes in critical care environments.